EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer

J N Zamarbide Losada, E Sulpice, S Combe, G S Almeida, D A Leach iD, J Choo, L Protopapa, M P Hamilton, S McGuire, X Gidrol iD, C L Bevan iD, C E Fletcher iD

Journal of Endocrinology · 2023

DOI: 10.1530/joe-22-0229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endocrinology, 2023. Verfasst von J N Zamarbide Losada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, U…. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most diagnosed cancer in women worldwide. In estrogen receptor (ER)-positive disease, anti-estrogens and aromatase inhibitors (AI) improve patient survival; however, many patients develop resistance. Dysregulation of apoptosis is a common resistance mechanism; thus, agents that can reinstate the activity of apoptotic pathways represent promising therapeutics for advanced drug-resistant disease. Emerging targets in this scenario include microRNAs (miRs). To identify miRs modulating apoptosis in drug-responsive and -resistant BC, a high-throughput miR inhibitor screen was performed, followed by high-content screening microscopy for apoptotic markers. Validation demonstrated that miR-361-3p inhibitor significantly increases early apoptosis and reduces proliferation of drug-responsive (MCF7), plus AI-/antiestrogen-resistant derivatives (LTED, TamR, FulvR), and ER- cells (MDA-MB-231). Importantly, proliferation-inhibitory effects were observed in vivo in a xenograft model, indicating the potential clinical application of miR-361-3p inhibition. RNA-seq of tumour xenografts identified FANCA as a direct miR-361-3p target, and validation suggested miR-361-3p inhibitor effects might be mediated in part through FANCA modulation. Moreover, miR-361-3p inhibition resulted in p53-mediated G1 cell cycle arrest through activation of p21 and reduced BC invasion. Analysis of publicly available datasets showed miR-361-3p expression is significantly higher in primary breast tumours vspaired normal tissue and is associated with decreased overall survival. In addition, miR-361-3p inhibitor treatment of BC patient explants decreased levels of miR-361-3p and proliferation marker, Ki67. Finally, miR-361-3p inhibitor showed synergistic effects on BC growth when combined with PARP inhibitor, Olaparib. Together, these studies identify miR-361-3p inhibitor as a potential new treatment for drug-responsive and -resistant advanced BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMicroRNAsHumansFemaleDrug Resistance, NeoplasmEstrogen AntagonistsAromatase InhibitorsApoptosisCell ProliferationGene Expression Regulation, NeoplasticCell Line, Tumor

Stichwörter der Autor:innen

MicroRNAapoptosisbreast cancercell cycledrug resistancenon-coding RNA

Substanzen

MicroRNAsEstrogen AntagonistsAromatase InhibitorsMIRN361 microRNA, human

Autor:innen und Institutionen

  • Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
  • Université Grenoble Alpes, CEA, INSERM, BIG, BGE, Grenoble, France.
  • Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: D A Leach, X Gidrol, C L Bevan, C E Fletcher

Zitieren

APA

Zamarbide Losada, J. N., Sulpice, E., Combe, S., Almeida, G. S., Leach, D. A., Choo, J., Protopapa, L., Hamilton, M. P., McGuire, S., Gidrol, X., Bevan, C. L., & Fletcher, C. E. (2023). Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer. Journal of Endocrinology. https://doi.org/10.1530/joe-22-0229

Vancouver

Zamarbide Losada JN, Sulpice E, Combe S, Almeida GS, Leach DA, Choo J, et al. Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer. Journal of Endocrinology. 2023. doi:10.1530/joe-22-0229

BibTeX
@article{ZamarbideLosada2023,
  author = {Zamarbide Losada, J N and Sulpice, E and Combe, S and Almeida, G S and Leach, D A and Choo, J and Protopapa, L and Hamilton, M P and McGuire, S and Gidrol, X and Bevan, C L and Fletcher, C E},
  title = {Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer},
  journal = {Journal of Endocrinology},
  year = {2023},
  doi = {10.1530/joe-22-0229}
}
Kostenlos starten →